Core Insights - Ultragenyx Pharmaceutical Inc. has sold an additional 25% of its royalty interest in Crysvita® for $400 million to OMERS, a major Canadian pension plan, which will begin receiving this royalty in January 2028 [1][2] - The proceeds from this transaction will support four expected product launches and contribute to the company's growth strategy, aiming for full-year GAAP profitability by 2027 [2] - Crysvita® has generated over $4 billion in cumulative sales in the U.S. and Canada, treating more than 3,000 patients since its launch [2] Financial Details - The new agreement with OMERS caps total payments at 1.55 times the purchase price, following a previous agreement that capped payments at 1.45 times [1] - OMERS will continue to receive 30% of Crysvita® net sales in the U.S. and Canada after the previous agreement's cap is reached [1] Company Background - Ultragenyx is focused on developing therapies for serious rare and ultra-rare genetic diseases, with a diverse portfolio of approved medicines and treatment candidates [4][5] - The company has a management team experienced in rare disease therapeutics and emphasizes efficient drug development [5] Partnership Insights - OMERS Life Sciences specializes in providing royalty financing and non-dilutive solutions to biopharma companies, aligning with its strategy of delivering steady, long-term returns to its members [6][7] - The partnership with Ultragenyx reflects OMERS' commitment to investing in the life sciences sector and supporting innovative treatments for rare diseases [2][6]